Intravitreal Bevacizumab versus Triamcinolone Acetonide for Exudative Age-Related Macular Degeneration

Publisher： Karger

E-ISSN： 1423-0259|41|1|21-27

ISSN： 0030-3747

Source： Ophthalmic Research, Vol.41, Iss.1, 2008-10, pp. : 21-27

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intravitreal Triamcinolone Acetonide for Exudative Age-Related Macular Degeneration among Japanese Patients

By  

Ophthalmologica, Vol. 220, Iss. 2, 2006-02 ,pp. : 118-124

Karger

Access to resources Recommend Favorite

Repeated Intravitreal Injection of Triamcinolone for Exudative Age-Related Macular Degeneration

By  

Ophthalmic Research, Vol. 38, Iss. 6, 2006-11 ,pp. : 324-328

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab and Bevacizumab in Combination with Full-Fluence Verteporfin Therapy and Dexamethasone for Exudative Age-Related Macular Degeneration

By  

Ophthalmic Research, Vol. 45, Iss. 3, 2010-09 ,pp. : 129-134

Karger

Access to resources Recommend Favorite

Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab

By  

Ophthalmologica, Vol. 225, Iss. 4, 2011-02 ,pp. : 211-221

Karger

Access to resources Recommend Favorite

Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 370-375

Karger

Access to resources Recommend Favorite